Knowledge Library

Adenoassociated virus (AAV) is a popular choice of viral vector for new gene therapies, but manufacturing systems have not kept pace with biological advances, leaving these therapies costly, difficult to produce at scale, and subject to inherent batch-to-batch variability. In this webinar, Dr. Weiheng Su describes how rethinking AAV manufacture “from the ground up” allowed …Read More >

We are all keenly aware that viruses can negatively impact our lives, but what about viruses that shape our existence and even improve some of its outcomes? In the past several decades, advances in cell and gene therapies have exploded due to innovations with adeno-associated virus (AAV). Yet, given its small genomic size, the life …Read More >

Throughout much of the development in ex vivo gene therapies, Lentiviral vectors have been a preferred vehicle due to their ability to integrate into the host cell genome and infect dividing as well as non-dividing cells. With the continued evolution of CAR-T therapies to include new modalities such as allogeneic and in vivo treatments, flexible …Read More >

For developers involved in AAV therapeutics, three key considerations are critical to successful commercialization: Quality, Quantity, and Speed.  In this webinar, Dr. Jason King demonstrate how OXGENE’s AAV plasmid system together with WuXi ATU’s AAV suspension manufacturing platform delivers higher titers and improved quality compared to industry standard in any serotype, at any scale and …Read More >

 In recent years, the demand for cell and gene therapy has increased substantially. With the success in gene and cell therapy has also increased demand for plasmid DNA. In supplying the industry with high-quality Plasmid DNA, key prominent market challenges are capacity availability, accelerated TAT and affordability. In this presentation, WuXi Advanced Therapies will …Read More >